First new type of treatment for schizophrenia in decades - NPR
Sep 27, 2024 — For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by Bristol Myers Squibb will be called...
Schizophrenia drug KarXT wins FDA approval - USA TODAY
Sep 26, 2024 — Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients...
The FDA approves a new type of schizophrenia drug : NPR
Sep 27, 2024 — The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
FDA Approves Cobenfy, A First In-Class Agent for Schizophrenia
Sep 27, 2024 — The US Food and Drug Administration approved Cobenfy, formerly known as KarXT (xanomeline-trospium), a first in-class agent for the treatment of schizophrenia. 1 Cobenfy is the first new agent with a novel mechanism of action for schizophrenia more than 50 years.
Bristol Myers Squibb - Bristol Myers Squibb Presents New Pooled …
Apr 6, 2024 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
FDA approves first schizophrenia drug with new mechanism of …
Sep 26, 2024 — The FDA has approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy) — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia.
The Latest Updates on KarXT - Psychiatric Times
May 3, 2024 — Kakar considers KarXT a first in class for muscarinic agonists. Kakar also shares why he is excited about the upcoming 2024 American Psychiatric Association Annual Meeting as a clinician and clinical researcher, including the new agents in development.
FDA weighs KarXT, first schizophrenia drug shift in decades - Axios
Sep 26, 2024 — Experts say the FDA is likely to approve the drug. KarXT could make BMS an estimated $8.2 billion by the end of the decade, the Financial Times reported.
Bristol Myers Squibb Reveals Promising Data for KarXT, a
Apr 9, 2024 — Bristol Myers Squibb announced results from its Phase III EMERGENT-4 trial analyzing the long-term efficacy, safety, and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia, which was showcased at the Annual Congress of the Schizophrenia International Research Society (SIRS).
Why This Potential New Medication for Schizophrenia Is Important
Feb 6, 2024 — In a paper recently published in the journal Lancet, Inder Kaul and colleagues reported results of a phase-3 clinical trial of xanomeline-trospium (KarXT) in the treatment of individuals...